As psychiatry struggles to develop new, more effective treatments, clinical trials combining psychotherapy and the drug MDMA, also known as Ecstasy, are producing stunning results. New research suggests that incorporating psychedelics like MDMA and psilocybin into talk therapy can dramatically boost outcomes with an array of issues, including PTSD, anxiety, depression, relationship blocks, even drug addiction. If ongoing trials continue with favourable results, FDA approval for certified therapists to use MDMA- and psilocybin-assisted therapy in their practices could be on the horizon. Guided in this workshop by the psychiatrist at the helm of the MDMA-assisted psychotherapy trials, you’ll explore:
The rationale for using drugs like MDMA, psilocybin and other psychedelics as catalysts for psychotherapy
The MDMA-assisted psychotherapy process, illustrated with video clips
How these inner-directed approaches to therapy respect and support clients' innate healing intelligence
New opportunities for psychotherapists to receive training in this approach
Continuing Professional Development Certificates
- PESI Australia, in collaboration with PESI in the USA, offers quality online continuing professional development events from the leaders in the field at a standard recognized by professional associations including psychology, social work, occupational therapy, alcohol and drug professionals, counselling and psychotherapy. On completion of the training, a Professional Development Certificate is issued after the individual has answered and submitted a quiz and course evaluation. This online program is worth 1.5 hours CPD.
Michael Mithoefer, MD, clinical assistant professor of psychiatry at the Medical University of South Carolina. In 2009, he completed & published the first FDA approved clinical trial of MDMA assisted psychotherapy for treatment-resistant PTSD, followed by completion of a Phase II trial. He is overseeing a multisite Phase III study of MDMA-assisted psychotherapy in 13 sites around the US (including the Trauma Research Foundation), and another MDMA-assisted psychotherapy multisite study in Europe and Israel.
Financial: Michael Mithoefer receives a salary and grants from MAPS Public Benefit Corp and is a clinical assistant professor at the Medical University of South Carolina.
Non-financial: Michael Mithoefer is a member of the non-profit MAPS.
Access for Self-Study (Non-Interactive)
Access never expires for this product.
Evaluate the results of clinical trials of MDMA-assisted psychotherapy for PTSD and their treatment implications.
Determine the clinical uses of MDMA-assisted psychotherapy in the treatment of trauma.
Appraise the role therapists play in the sessions while the client is under the effects of these drugs, and how to facilitate the talk-therapy sessions that precede and follow it to improve client outcomes.
Assess the risks and limitations of MDMA and psilocybin-assisted psychotherapy.
History of MDMA and Psilocybin
Physiological effects and side effects, risk/benefit profile
Design of past and ongoing non-profit-sponsored clinical trials of MDMA-assisted psychotherapy
Results of Six Completed MDMA Phase 2 Clinical trials
Design of ongoing Phase 3 Trials of MDMA-assisted psychotherapy
Overview of psilocybin clinical trials
Status of FDA drug development – MDMA and Psilocybin, including Breakthrough Therapy Designation
The manualized therapeutic method used in clinical trials of MDMA-assisted psychotherapy
Essential elements of “inner directed” approach
Illustrated elements of “inner directed” approach
Challenges that may arise
Therapist training program for MDMA-assisted psychotherapy
Additional Participant CE must be purchased for each additional viewer. These viewers will watch the video with the main registrant, but will have individual access to course handouts and certification. The standard price of this program includes certification for main viewer.